These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22184635)

  • 1. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses.
    Yang D; Postnikov YV; Li Y; Tewary P; de la Rosa G; Wei F; Klinman D; Gioannini T; Weiss JP; Furusawa T; Bustin M; Oppenheim JJ
    J Exp Med; 2012 Jan; 209(1):157-71. PubMed ID: 22184635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-mobility group nucleosome binding domain 1 (HMGN1) functions as a Th1-polarizing alarmin.
    Yang D; Han Z; Alam MM; Oppenheim JJ
    Semin Immunol; 2018 Aug; 38():49-53. PubMed ID: 29503123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant.
    Wei F; Yang D; Tewary P; Li Y; Li S; Chen X; Howard OM; Bustin M; Oppenheim JJ
    Cancer Res; 2014 Nov; 74(21):5989-98. PubMed ID: 25205103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Mobility Group Nucleosome-Binding Protein 1 as Endogenous Ligand Induces Innate Immune Tolerance in a TLR4-Sirtuin-1 Dependent Manner in Human Blood Peripheral Mononuclear Cells.
    Arts RJW; Huang PK; Yang D; Joosten LAB; van der Meer JWM; Oppenheim JJ; Netea MG; Cheng SC
    Front Immunol; 2018; 9():526. PubMed ID: 29593748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release mechanism of high mobility group nucleosome binding domain 1 from lipopolysaccharide-stimulated macrophages.
    Murakami T; Hu Z; Tamura H; Nagaoka I
    Mol Med Rep; 2016 Apr; 13(4):3115-20. PubMed ID: 26935015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High mobility group nucleosome binding protein 1 (HMGN1) induces activation of mouse BV2 microglia and upregulates their pro-inflammatory mediator expression by activating TLR4/MyD88/NF-κB p65/IKK-β signal pathway].
    Mao Y; Yu J; Yuan J; DA J; Yu F; Zha Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Feb; 40(2):135-141. PubMed ID: 38284254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMGN1 and R848 Synergistically Activate Dendritic Cells Using Multiple Signaling Pathways.
    Alam MM; Yang D; Trivett A; Meyer TJ; Oppenheim JJ
    Front Immunol; 2018; 9():2982. PubMed ID: 30619338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endotoxin-induced maturation of MyD88-deficient dendritic cells.
    Kaisho T; Takeuchi O; Kawai T; Hoshino K; Akira S
    J Immunol; 2001 May; 166(9):5688-94. PubMed ID: 11313410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin.
    Tewary P; Yang D; de la Rosa G; Li Y; Finn MW; Krensky AM; Clayberger C; Oppenheim JJ
    Blood; 2010 Nov; 116(18):3465-74. PubMed ID: 20660289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.
    Park SN; Noh KT; Jeong YI; Jung ID; Kang HK; Cha GS; Lee SJ; Seo JK; Kang DH; Hwang TH; Lee EK; Kwon B; Park YM
    Exp Mol Med; 2013 Feb; 45(2):e8. PubMed ID: 23392255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the alarmin HMGN1 for anticancer therapy.
    Yang D; Bustin M; Oppenheim JJ
    Immunotherapy; 2015; 7(11):1129-31. PubMed ID: 26567750
    [No Abstract]   [Full Text] [Related]  

  • 12. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.
    Davis MB; Vasquez-Dunddel D; Fu J; Albesiano E; Pardoll D; Kim YJ
    Clin Cancer Res; 2011 Jun; 17(12):3984-92. PubMed ID: 21543518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMGN1 down-regulation in the diabetic kidney attenuates tubular cells injury and protects against renal inflammation via suppressing MCP-1 and KIM-1 expression through TLR4.
    Yu J; Da J; Yu F; Yuan J; Zha Y
    J Endocrinol Invest; 2024 Apr; 47(4):1015-1027. PubMed ID: 38409569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex.
    Okamoto N; Mizote K; Honda H; Saeki A; Watanabe Y; Yamaguchi-Miyamoto T; Fukui R; Tanimura N; Motoi Y; Akashi-Takamura S; Kato T; Fujishita S; Kimura T; Ohto U; Shimizu T; Hirokawa T; Miyake K; Fukase K; Fujimoto Y; Nagai Y; Takatsu K
    J Biol Chem; 2017 Sep; 292(37):15378-15394. PubMed ID: 28754693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.
    Xiao L; Kim J; Lim M; Dai B; Yang L; Reed SG; Baltimore D; Wang P
    Vaccine; 2012 Mar; 30(15):2570-81. PubMed ID: 22314134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated apoptotic cells induce dendritic cell maturation via engagement of Toll-like receptor 4 (TLR4), dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN), and β2 integrins.
    Pathak SK; Sköld AE; Mohanram V; Persson C; Johansson U; Spetz AL
    J Biol Chem; 2012 Apr; 287(17):13731-42. PubMed ID: 22396536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturation.
    Hu W; Jain A; Gao Y; Dozmorov IM; Mandraju R; Wakeland EK; Pasare C
    Proc Natl Acad Sci U S A; 2015 Nov; 112(45):13994-9. PubMed ID: 26508631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endotoxin can induce MyD88-deficient dendritic cells to support T(h)2 cell differentiation.
    Kaisho T; Hoshino K; Iwabe T; Takeuchi O; Yasui T; Akira S
    Int Immunol; 2002 Jul; 14(7):695-700. PubMed ID: 12096028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8
    Chen CY; Ueha S; Ishiwata Y; Shichino S; Yokochi S; Yang D; Oppenheim JJ; Ogiwara H; Deshimaru S; Kanno Y; Aoki H; Ogawa T; Shibayama S; Matsushima K
    Cancer Immunol Res; 2021 Oct; 9(10):1214-1228. PubMed ID: 34344641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice.
    Zuo B; Qi H; Lu Z; Chen L; Sun B; Yang R; Zhang Y; Liu Z; Gao X; You A; Wu L; Jing R; Zhou Q; Yin H
    Nat Commun; 2020 Apr; 11(1):1790. PubMed ID: 32286296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.